Cutaneous reactions secondary to STAT3 inhibition were less expected given the Janus kinase (JAK)-STAT pathway and the role of JAK inhibition as an important therapeutic tool in many dermatologic inflammatory conditions, including psoriasis and atopic dermatitis.10 The gene discussed is SOAT1; the disease is atopic eczema.